Relay Therapeutics

Integrating leading-edge computational and experimental science to transform human health. $RLAY

[Relay Therapeutics @Relay_Tx]

May is Lymphatic Malformation Awareness Month, a month dedicated to raising awareness and understanding of the two types of lymphatic malformations: isolated lymphatic malformations and complex lymphatic anomalies. At Relay Tx, we recognize the impact lymphatic malformations can have on individuals and families and remain committed to advancing research for the lymphatic malformations and broader vascular anomalies community.

Learn more about lymphatic malformations and support available to the lymphatic malformation community from the patient advocacy group, @LGDAlliance: https://t.co/6X9UnJoGEA

[LGDAlliance @LGDAlliance]

Understanding starts here. 💜

For many families, LM and CLA bring more questions than answers. This month, we’re helping change that—through awareness, support, and community.

Learn more: https://t.co/Wn6AwY8taK

#LMAwarenessMonth #MakeRareVisible #RareButNotAlone

[Relay Therapeutics @Relay_Tx]

Today, we announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies, a group of rare disorders characterized by abnormal development of blood vessels, lymphatic vessels, and surrounding tissues. The data, being presented this week at #ISSVA2026, demonstrated symptomatic improvement at 12 weeks in nearly all patients while maintaining a safety and tolerability profile showing potential for chronic use. These findings also support the potential advantage of PI3Kα mutant-selective inhibition. Click below for additional insights and more from President of R&D Don Bergstrom. https://t.co/OhAcGFoNJV

[Relay Therapeutics @Relay_Tx]

Today, we reported first quarter 2026 financial results and highlighted continued progress across our pipeline. Details here. https://t.co/4Hi3Mfprxp

[Relay Therapeutics @Relay_Tx]

Today, we're pleased to announce new clinical data and plans to move zovegalisib + atirmociclib triplet combination into Phase 3 development in frontline patients with PI3Kα-mutated, HR+/HER2- metastatic #breastcancer. We aim to initiate this study early next year. Join us this morning, April 27, at 8:30am ET for our conference call to learn more. https://t.co/eT7plAyP1b

[Relay Therapeutics @Relay_Tx]

In continued recognition of International Children’s Book Day, Relay Tx acknowledges that children’s books can help communicate feelings and experiences related to rare diseases that are often hard to explain.

For families living with vascular anomalies, everyday life can include navigating uncertainty, feelings of isolation, and comments about visible differences that can feel overwhelming, especially for children. By honestly explaining these unique journeys and experiences, children's books can help empower individuals and build understanding and acceptance.

Today, we celebrate stories that shine a light on rare conditions and remind families that their experiences matter. They are not alone.

Learn more about vascular anomalies children’s books and CLOVES Syndrome at https://t.co/z6d1TsPqqw and FAVA at https://t.co/llSfBKRIWx.

[Relay Therapeutics @Relay_Tx]

In the spirit of International Children’s Book Day last week, Relay Tx recognizes the power of children’s books to explain challenging topics in ways that are honest and compassionate.

For families impacted by breast cancer, children's books can help open dialogue, normalize emotions, and remind families that they are not alone. These books can be a gentle way to support understanding, resilience, and connection during challenging moments.

So today, we honor the authors, illustrators, patients, and families who use storytelling as a tool for comfort, courage, and care.

Learn more about children’s books available for the breast cancer community: https://t.co/06u7CtpSEM

[Relay Therapeutics @Relay_Tx]

New today: We’ve published a webinar focused on Vascular Anomalies education, intended to support broader understanding of the disease area, existing therapeutic options & ongoing clinical development of zovegalisib, our mutant-selective PI3Kα inhibitor. https://t.co/TEfOxgwKai

[Relay Therapeutics @Relay_Tx]

More: https://t.co/v93x5hCsJ7

[Relay Therapeutics @Relay_Tx]

We're pleased to share Ph1/2 data from the ReDiscover trial at the 400mg BID fed dose of zovegalisib+fulvestrant in patients w/ PI3Kα-mutated, HR+/HER2- metastatic #breastcancer at ESMO TAT, supporting our decision to advance this regimen into the ongoing Ph3 ReDiscover-2 trial.

[Relay Therapeutics @Relay_Tx]

We were on the ground at #MBCC26 & were grateful for the opportunity to connect with investigators, research partners, & the #breastcancer community as we continue advancing innovative therapies for patients. Thanks to all who joined for our ReDiscover and ReDiscover-2 posters.

[Relay Therapeutics @Relay_Tx]

We were pleased to host BOD member Linda Hill & her coauthor Emily Tedards, as part of a tour for their new book “Genius at Scale.” They shared insights on building innovative companies by creating trust, encouraging bold ideas & fostering collaboration. Thank you Linda & Emily!

[Relay Therapeutics @Relay_Tx]

Today, we are pleased to report fourth quarter and full year 2025 financial results along with anticipated 2026 milestones. Listen below as CEO @SanjivKPatel1 shares more about the year ahead. Full details here. https://t.co/WoqpfvckoK

[Relay Therapeutics @Relay_Tx]

Ahead of #RareDiseaseDay, we gathered to better understand rare diseases & experiences of those living with them. As we advance our research in vascular anomalies & Fabry disease, we are today reminded of the unmet need in rare diseases & reinforce our commitment to patients.

[Relay Therapeutics @Relay_Tx]

Relay Tx was excited to join the kickoff session for the @CLOVESSyndrome International CLOVES Summit. As the event sponsor, we're grateful to participate in an event that will bring together patients, families, and researchers. Learn more about the summit: https://t.co/JTl8dsqbfg

[Relay Therapeutics @Relay_Tx]

We will present initial Phase 1/2 data of zovegalisib plus fulvestrant at the 400mg BID fed dose (the Phase 3 dose) in CDK4/6-experienced patients this March at #ESMOTAT26. Details here: https://t.co/zRTc0gcxCq

[Relay Therapeutics @Relay_Tx]

Today, we announced that the US FDA has granted zovegalisib Breakthrough Therapy Designation for PIK3CA-mutant, HR+/HER2- advanced #breastcancer, supported by data from our ReDiscover trial testing zovegalisib at the 600mg BID fasted & 400mg BID fed doses in combo w/ fulvestrant.

[Relay Therapeutics @Relay_Tx]

Santa only puts in one long shift.

Relayers put in a full year of dedication.

2025 was a busy one and now it’s time to slow down, recharge, and celebrate with family, friends, and our little pastry chefs!

[Relay Therapeutics @Relay_Tx]

Today at #SABCS25, we are pleased to announce an efficacy subset analysis of zovegalisib (RLY-2608) + fulvestrant from the Phase 1/2 ReDiscover trial in PI3Kα-mutated, metastatic #breastcancer patients. Learn more here. https://t.co/cgnX5HaLJQ

[Relay Therapeutics @Relay_Tx]

Join us at #SABCS25 this week! We look forward to sharing the latest updates from our ongoing #breastcancer clinical trials this Friday. More details below.

[Relay Therapeutics @Relay_Tx]

Before Relayers brave the Thanksgiving traffic 🚗

Before we soak the turkey in a brine 🦃

Employees soaked in the spirit of gratitude, writing handwritten thank notes to colleagues across the organization 📨

Who doesn't like getting mail!? 📬

Happy Thanksgiving!